Skip to main content
. Author manuscript; available in PMC: 2018 May 6.
Published in final edited form as: Biochem Biophys Res Commun. 2017 Mar 19;486(3):659–664. doi: 10.1016/j.bbrc.2017.03.086

Figure 3. CREB activates the IP3R2 promoter via binding to CRE4 and 5.

Figure 3

(a) Schematic illustrating the five putative CRE sites in the IP3R2 promoter. (b) HepG2 cells transfected with 1.5 kb or 1.0 kb segments of the IP3R2 promoter showed >20-fold greater activity when co-transfected with CREB, relative to empty vector (*p<0.0001, n=4), while mutation of CRE4, CRE5, or both markedly reduced activation by CREB (#p<0.001, n=4). There was no effect when CRE sites 1, 2 or 3 were mutated (not shown). (c) Summary of qPCR ChIP assay experiments shows that there was no enrichment in the CREB binding to CRE’s 1 and 2–3 over IgG control, but CREB binding was higher to CRE4 and 5. The increase was significant for CRE5 (*p<0.01, n=3) and marginally significant for CRE4 (0.1>p>0.05, n=3) compared to IgG. (d) Representative ChIP assay.